The Pharmacist’s Role in Opioid Analgesia: Supporting the Pain Patient While Preventing Overdose, Misuse, and Diversion

Mara N. Villanueva, PharmD
Published Online: Wednesday, July 16, 2014
Follow Pharmacy_Times:
This activity is supported by educational grants from Purdue Pharma LP, Teva Pharmaceuticals, and Zogenix, Inc.

The Pharmacist’s Role in Opioid Analgesia: Supporting the Pain Patient While Preventing Overdose, Misuse, and Diversion

Faculty
Mara N. Villanueva, PharmD
Clinical Pharmacy Specialist
Pharmacy Medication Management
and Analytics
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Educational Objectives
At the conclusion of this educational activity, participants should be able to:
  • Examine the risk factors associated with the highest rates of opioid overdose.
  • Identify the characteristics and red flags of patients who intend to use or distribute opioids for non-medical reasons.
  • Review the information that is important to communicate to patients regarding appropriate opioid medication use, storage, and disposal.
  • Describe how pharmacists can support the current Risk Evaluation and Mitigation Strategy programs for extended-release, long-acting, and transmucosal immediate-release fentanyl opioid products, and identify the tools available to prevent opioid misuse, diversion, and abuse.
Intended Audience
Pharmacists

Release date: July 8, 2014
Expiration date: July 8, 2016
Estimated time to complete activity: 1.5 hours
Fee: Free

Click here to view this activity.
Click here to view this activity. - See more at: http://www.pharmacytimes.com/publications/issue/2014/June2014/Optimizing-the-Management-of-Asthma-The-Critical-Role-of-the-Pharmacist#sthash.7ZeRdjp8.dpuf
Click here to view this activity.

Description: Pharmacy Times/Ascend Media Office of Continuing Professional EducationPharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-14-062-H03-P. The activity is available for CE credit through July 8, 2016.

Related Articles
Four states are reporting recent progress on preventing pseudoephedrine diversion after implementing a real-time, stop-sale tracking system.
Even short-term treatment with nonsteroidal anti-inflammatory drugs is associated with significant increases in bleeding and cardiovascular event risk in patients receiving antithrombotic therapy after a heart attack.
Most people hear “hospice” and think “cancer,” but many end-stage chronic obstructive pulmonary disease patients also receive hospice care when their caregivers can no longer provide the medical attention they need.
Lightlake Therapeutics recently announced that the FDA has granted Fast Track designation to Adapt Pharma’s intranasal naloxone, an opioid overdose reversal agent.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$